A multicenter, placebo-controlled, double-blind, multiple-crossover study of Fentanyl Pectin Nasal Spray (FPNS) in the treatment of breakthrough cancer pain

Abstract 

This randomized, double-blind, crossover study assessed the efficacy and tolerability of a new rapid onset nasal fentanyl formulation (Fentanyl Pectin Nasal Spray; FPNS) for breakthrough cancer pain (BTCP). Eighty-three of 114 patients experiencing one to four BTCP episodes/day while taking ⩾60mg/day of oral morphine or equivalent successfully identified an effective dose of FPNS during a titration phase and entered a double-blind phase in which 10 BTCP episodes were treated with this effective dose (7) or placebo (3). Compared with placebo, FPNS significantly improved mean summed pain intensity difference (SPID) from 10min (P<0.05) until 60min (P<0.0001), including the primary endpoint at 30min (P<0.0001). FPNS significantly improved pain intensity (PI) scores as early as 5min (P<0.05); pain intensity difference (PID) from 10min (P<0.01); and pain relief (PR) scores from 10min (P<0.001). More patients showed a clinically meaningful (⩾2-point reduction in PI) pain reduction from 10min onward (P⩽0.01) and 90.6% of the FPNS-treated versus 80.0% of placebo-treated BTCP episodes did not require rescue medication (P<0.001). Approximately 70% of patients were satisfied or very satisfied with the convenience and ease of use of FPNS. Only 5.3% of patients withdrew from treatment due to adverse events, no significant nasal effects were reported, and 87% of patients elected to continue open-label treatment post-study. In this short-term study, FPNS was safe, well tolerated, and rapidly efficacious for BTCP.

Keywords: Breakthrough pain, Cancer pain, Fentanyl Pectin Nasal Spray, Intranasal opioid, Rapidonset opioid